Kevin D. Read

DDU384: A new preclinical candidate for the treatment of Tuberculosis

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

Use of a cytochrome P450 humanised mouse model to refine schistosomiasis drug discovery.

A cytochrome P450 humanised mouse model is used to study Schistosoma mansoni development, schistosomiasis, drug metabolism and drug efficacy.

Small molecule inhibitors of the NorA multidrug efflux pump potentiate antibiotic activity by binding the outward-open conformation

The paper identifies IMP-2380, a potent NorA inhibitor that enhances antibiotic activity by stabilizing the outward-open conformation of the efflux pump.

Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalling

This paper designs and evaluates Dyr726, a brain-penetrant multi-kinase inhibitor that targets PI3Kα, receptor tyrosine kinases, and WNT signaling, showing efficacy in preclinical cancer models.